Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Moderna, Inc.
  6. News
  7. Summary
    MRNA   US60770K1079


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Moderna : India's vaccinations plummet as coronavirus infections soar

05/04/2021 | 01:32am EDT
FILE PHOTO: Vial and sryinge are seen in front of displayed Pfizer logo

(Corrects third paragraph to say India has partially or fully immunised only 9.5% of its 1.35 billion people, not 12%.)

By Krishna N. Das

NEW DELHI (Reuters) - India's daily COVID-19 shots have fallen sharply from an all-time high reached early last month as domestic companies struggle to boost supplies and imports are limited, even as the country fights the world's worst surge in infections.

Daily inoculations have averaged 2.5 million since hitting a peak of 4.5 million on April 5. A quadrupling of coronavirus cases during the period has collapsed the public health system in many regions of the country.

India, with the world's biggest vaccine making capacity, has partially or fully immunised only 9.5% of its 1.35 billion people, according to data from the government's Co-Win https://dashboard.cowin.gov.in portal.

Public forecasts by its only two current vaccine producers show their total monthly output of 70-80 million doses would increase only in two months or more, though the number of people eligible for vaccines has doubled to an estimated 800 million since May 1.

India on Saturday received 150,000 doses of Russia's Sputnik V vaccine and the government said "millions of doses" more will come in.

Pfizer said on Monday it was in discussions with the Indian government seeking an "expedited approval pathway" for its vaccine.

"Unfortunately, our vaccine is not registered in India although our application was submitted months ago," CEO Albert Bourla said.

"We are currently discussing with the Indian government an expedited approval pathway to make our Pfizer-BioNTech vaccine available for use in the country."

Pfizer was the first company to seek emergency use authorisation for its vaccine in India late last year. It withdrew its application in February after the drugs regulator sought a small, local safety study for the shot before considering its request.

But as cases surged, India said last month it would fast-track approval for some foreign shots, with companies now required to do a local trial https://pib.gov.in/PressReleaseIframePage.aspx?PRID=1711979 within 30 days of approval, not before.

GlobalData analyst Prashant Khadayate said Pfizer will become a "vaccine of choice among people who can afford it" but that its need to be stored in ultra-low temperatures would be a challenge.

India has also invited Johnson & Johnson and Moderna to sell their vaccines to the country.

(Reporting by Krishna N. Das; Additional reporting by Manash Mishra; Editing by Tom Hogue and Nick Macfie)

© Reuters 2021
All news about MODERNA, INC.
05/09MODERNA  : First of three S.Korea expert panels recommends approval of Moderna C..
05/09First of three south korea expert panels recommends approval of moderna covid..
05/09MODERNA  : U.S. CDC Says Delivered 329,843,825 Doses Of COVID-19 Vaccine As Of M..
05/09MODERNA  : U.S. administers 259.7 mln doses of COVID-19 vaccines –CDC
05/09Some Countries Shift Guidance on AstraZeneca Vaccine
05/08MODERNA  : All adults can book COVID vax at select Ontario hot spot pharmacies
05/08MODERNA  : U.S. CDC Says Delivered 329,840,055 Doses Of Covid-19 Vaccine As Of M..
05/08MODERNA  : U.S. administers 257.3 mln doses of COVID-19 vaccines –CDC
05/08Who have provinces pegged to receive COVID-19 vaccines in the coming weeks?
05/07Correction to Impact of U.S. Support for Patent Waiver on Vaccine Makers Arti..
More news
Financials (USD)
Sales 2021 18 212 M - -
Net income 2021 10 334 M - -
Net cash 2021 12 094 M - -
P/E ratio 2021 6,58x
Yield 2021 -
Capitalization 65 346 M 65 346 M -
EV / Sales 2021 2,92x
EV / Sales 2022 2,90x
Nbr of Employees 1 300
Free-Float 88,7%
Duration : Period :
Moderna, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MODERNA, INC.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 17
Average target price 166,20 $
Last Close Price 163,15 $
Spread / Highest target 41,6%
Spread / Average Target 1,87%
Spread / Lowest Target -49,1%
EPS Revisions
Managers and Directors
Stéphane Bancel Chief Executive Officer & Director
Stephen Hoge President
David W. Meline Chief Financial Officer
Noubar B. Afeyan Chairman
Juan Andres Chief Technical Operations & Quality Officer
Sector and Competitors
1st jan.Capitalization (M$)
MODERNA, INC.56.17%65 346
LONZA GROUP AG1.51%47 533
CELLTRION, INC.-25.77%32 687
SEAGEN INC.-20.36%25 314
CUREVAC N.V.23.84%21 497